Current Issue : January - March Volume : 2018 Issue Number : 1 Articles : 5 Articles
Background: Patients could develop endocrine and exocrine pancreatic insufficiency after acute pancreatitis (AP),\nbut the morbidity, risk factors and outcome remain unclear. The aim of the present study was to evaluate the\nincidence of endocrine and exocrine pancreatic insufficiency after AP and the risk factors of endocrine pancreatic\ninsufficiency through a long-term follow-up investigation.\nMethods: Follow-up assessment of the endocrine and exocrine function was conducted for the discharged patients\nwith AP episodes. Oral Glucose Tolerance Test (OGTT) and faecal elastase-1(FE-1) test were used as primary parameters.\nFasting blood-glucose (FBG), fasting insulin (FINS), glycosylated hemoglobin HBA1c, 2-h postprandial blood glucose\n(2hPG), Homa beta cell function index (HOMA-�²), homeostasis model assessment of insulin resistance (HOMA-IR) and\nFE-1 were collected. Abdominal contrast-enhanced computed tomography (CECT) was performed to investigate the\npancreatic morphology and the other related data during hospitalization was also collected.\nResults: One hundred thirteen patients were included in this study and 34 of whom (30.1%) developed diabetes\nmellitus (DM), 33 (29.2%) suffered impaired glucose tolerance (IGT). Moreover, 33 patients (29.2%) developed mild to\nmoderate exocrine pancreatic insufficiency with 100�¼g/g50%, WON and insulin resistance were the independent risk factors of\nnew onset diabetes after AP....
Background. Hepatic ischemia reperfusion (IR) injury is a common phenomenon in transplantation or trauma. The aim of the\npresent study was to determine the protective effect of quercetin (QE) on hepatic IR injury via the ERK/NF-�ºB pathway.\nMethods. Mice were randomized into the sham, IR, QE100 + IR, and QE200 + IR groups. Quercetin was administered\nintragastrically daily at two doses (100 mg/kg and 200 mg/kg) for 5 days prior to IR injury. The expression levels of liver\nenzymes, inflammatory cytokines, and other marker proteins were determined at 2, 8, and 24 hours after IR. And they were\ncompared among these groups. Results. Compared with the IR group, the treatment of QE reduced the release of cytokines,\nleading to inhibition of apoptosis and autophagy via downregulation of the ERK/NF-�ºB pathway in this model of hepatic\nIR injury. Conclusion. Apoptosis and autophagy caused by hepatic IR injury were inhibited by QE following a reduction in\nthe release of inflammatory cytokines, and the relationship between the two may be associated with inactivation of the\nERK/NF-�ºB pathway....
Background and Aims. To investigate the association between serum albumin levels within 24 hrs of patient admission and the\ndevelopment of persistent organ failure in acute pancreatitis. Methods. A total of 700 patients with acute pancreatitis were enrolled.\nMultivariate logistic regression and subgroup analysis determined whether decreased albumin was independently associated with\npersistent organ failure and mortality. The diagnostic performance of serum albumin was evaluated by the area under Receiver\nOperatingCharacteristic (ROC) curves. Results.As levels of serumalbumin decrease, the risk of persistent organ failure significantly\nincreases (...
Background and Aims. Functional gastrointestinal disorders (FGDs) are multifactorial disorders of the gut-brain interaction. This\nstudy investigated the prevalence of Axis I and spectrum disorders in patients with FGD and established the link between FGDs and\npsychopathological dimensions. Methods. A total of 135 consecutive patients with FGD were enrolled. The symptomsââ?¬â?¢ severity was\nevaluated using questionnaires, while the psychiatric evaluation by clinical interviews established the presence/absence of mental\n(Diagnostic and Statistical Manualââ?¬â?4th edition, Axis I Diagnosis) or spectrum disorders. Results. Of the 135 patients, 42\n(32.3%) had functional dyspepsia, 52 (40.0%) had irritable bowel syndrome, 21 (16.2%) had functional bloating, and 20 (15.4%)\nhad functional constipation. At least one psychiatric disorder was present in 46.9% of the patients, while a suprathreshold panic\nspectrum was present in 26.2%. Functional constipation was associated with depressive disorders (p < 0 05), while functional\ndyspepsia was related to the current major depressive episode (p < 0 05). Obsessive-compulsive spectrum was correlated with\nthe presence of functional constipation and irritable bowel syndrome (p < 0 05). Conclusion. The high prevalence of\nsubthreshold psychiatric symptomatology in patients with FGD, which is likely to influence the expression of gastrointestinal\nsymptoms, suggested the usefulness of psychological evaluation in patients with FGDs....
Background: None of current diagnostic methods has been proven to be a reliable tool for gastro-esophageal reflux\ndisease (GERD). Pepsin in saliva has been proposed as a promising diagnostic biomarker for gastro-esophageal reflux.\nWe aimed to determine the diagnostic value of salivary pepsin detection for GERD.\nMethods: Two hundred and fifty patients with symptoms suggestive of GERD and 35 asymptomatic healthy\nvolunteers provided saliva on morning waking, after lunch and dinner for pepsin determination using the\nPeptest lateral flow device. All patients underwent 24-h multichannel intraluminal impedance pH (24-h MII-pH)\nmonitoring and upper gastrointestinal endoscopy. Based on 24-h MII-pH and endoscopy study, patients were\ndefined as GERD (abnormal MII-pH results and/or reflux esophagitis) and non-GERD otherwise.\nResults: Patients with GERD had a higher prevalence of pepsin in saliva and higher pepsin concentration\nthan patients with non-GERD and healthy controls (P < 0.001 for all). The pepsin test had a sensitivity of 73%\nand a specificity of 88.3% for diagnosing GERD using the optimal cut-off value of 76 ng/mL. Postprandial\nsaliva samples collected when the symptoms occurred had a more powerful ability to identify GERD.\nConclusions: Salivary pepsin test had moderate diagnostic value for GERD. It may be a promising tool to replace the\nuse of currently invasive tools with advantages of non-invasive, easy to perform and cost effective.\nTrial registration: ChiCTR-DDD-16009506 (date of registration: October 20, 2016)....
Loading....